{"id":"W4366817647","doi":"10.1136/rmdopen-2022-002939","title":"Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study","year":2023,"lang":"en","type":"article","venue":"RMD Open","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Global Affairs Canada; Toronto Western Hospital; University of Toronto","funders":"Genentech; Medac; Biogen; Celgene; Gilead Sciences; National Institute for Health and Care Research; Novartis Pharma; Novartis; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; Sun Pharma; GlaxoSmithKline","keywords":"Secukinumab; Medicine; Psoriatic arthritis; Placebo; Quality of life (healthcare); Internal medicine; Physical therapy; Dermatology Life Quality Index; Body mass index; Presenteeism; Disease; Absenteeism; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001205922,0.0001494033,0.0003395424,0.00002930607,0.0001287632,0.00003923123,0.00005371388,0.00002533873,0.000005657015],"category_scores_gemma":[0.0001317204,0.0000711398,0.00001445934,0.0002450651,0.00006674662,0.0001776507,0.0001943893,0.0001100855,4.442136e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002809507,"about_ca_system_score_gemma":0.00007861695,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007767389,"about_ca_topic_score_gemma":0.001071849,"domain_scores_codex":[0.9989988,0.00009859023,0.0001579199,0.0003358064,0.0002656783,0.0001431867],"domain_scores_gemma":[0.9993215,0.0001083441,0.0001142455,0.0002585306,0.00007247962,0.0001249553],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1712327,0.00115241,0.8167241,0.00006786691,0.0002090637,0.00004311972,0.002879574,8.092737e-7,0.0001657802,0.000006951951,0.00009582939,0.007421799],"study_design_scores_gemma":[0.06813522,0.003543815,0.9217379,0.0001311187,0.000105136,1.591288e-7,0.006139835,0.00004684852,0.00003181648,0.00002422163,0.00001652031,0.00008741498],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973773,0.00002623417,2.517119e-7,0.0004490028,0.00002682986,0.001776044,0.0003039746,0.00001540242,0.00002491628],"genre_scores_gemma":[0.9995477,0.00001196024,0.00001404357,0.00003504073,0.00007022614,0.00003078561,0.0001878789,0.0000141875,0.0000881704],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1050138,"threshold_uncertainty_score":0.2900997,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01902606875253266,"score_gpt":0.3127914825420933,"score_spread":0.2937654137895607,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}